Treating an HIV-infected paediatric patient: An easy task?

Antiviral Therapy

Volumn 15, Issue 3, 2010, Pages 293-296

  Rakhmanina, Natella Y ^a,b   Van Den Anker, John N ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE PLUS EFAVIRENZ PLUS EMTRICITABINE; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CHILD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE; ADOLESCENT; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; PEDIATRICS; PRESCHOOL CHILD; PROCEDURES; VIROLOGY;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; INFANT; PEDIATRICS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77952925789     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1534     Document Type: Note

References (22)

1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. (Updated 23 February 2009. Accessed 21 October 2009.) Available from http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf
2. PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10:591-613.
3. World Health Organization. Preferred antiretroviral medicines for treating and preventing HIV infection in younger children: report of the WHO Paediatric Antiretroviral Working Group 2008. (Updated 20 May 2008. Accessed 20 October 2009.) Available from http://www.who.int/hiv/pub/paediatric/ARV-WG- meeting-report-may2008.pdf
4. Committee on Pediatric AIDS, Section on International Child Health. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 2007; 119:838-845.
5. Goode M, McMaugh A, Crisp J, et al. Adherence issues in children and adolescents receiving highly active antiretroviral therapy. AIDS Care 2003; 15:403-408.
6. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002; 109:e61.
7. Winnick S, Lucas DO, Hartman AL, et al. How do you improve compliance? Pediatrics 2005; 115:e718-e724. (Pubitemid 43843146)
8. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. J Acquir Immune Defic Syndr 2005;38:417-425. (Pubitemid 40381551)
9. LePrevost M, Green H, Flynn J, et al. Adherence and acceptability of once daily lamivudine and abacavir in human immunodeficiency virus type-1 infected children. Pediatr Infect Dis J 2006; 25:533-537. (Pubitemid 43863364)
10. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs 2008; 68:567-578.
11. Parienti JJ, Bangsberg DR, Verdon R, et al. Better adherence with once-daily antiretroviral regimens: a meta-analysis. Clin Infect Dis 2009; 48:484-488.
12. McKinney RE, Jr., Rodman J, Hu C, et al. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 2007; 120:e416-e423.
13. Scherpbier HJ, Bekker V, Pajkrt D, et al. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics 2007; 119:e705-e715. (Pubitemid 46407545)
14. Bergshoeff A, Burger D, Verweij C, et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005;10:239-246. (Pubitemid 41151030)
15. PENTA. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months. Antiviral Therapy 2010; 15:297-305.
16. Blaschke TF. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes. Curr Opin HIV AIDS 2008; 3:603-607.
17. Rosso R, Di Biagio A, Dentone C, et al. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J Antimicrob Chemother 2006; 57:1168-1171. (Pubitemid 44644421)
18. van der Lee M, Verweel G, de Groot R, et al. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Antivir Ther 2006;11:439-445.
19. van der Flier M, Verweel G, van der Knaap LC, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. Antivir Ther 2008; 13:1087-1090.
20. la Porte C, van Heeswijk R, Mitchell CD, et al. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children. Antivir Ther 2009; 14:603-606.
21. US Department of Health & Human Services. President's Emergency Plan for AIDS Relief: approved and tentatively approved antiretrovirals in association with the President's Emergency Plan. (Updated 09 March 2010. Accessed 21 October 2009.) Available from http://www.fda.gov/ InternationalPrograms/FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231. htm
22. L'Homme RF, Kabamba D, Ewings FM, et al. Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. AIDS 2008; 22:557-565.